The positive we can look forward to in the financials is that Intangible asset impairments should nearly be finished.
Mayne purchased the Teva generics portfolio in August 2016 for US $652M which is approx AU $867M on the 0.752 exchange rate at the time.
CGU (cash generating unit) impairments over the past 4 years are as follows
2018 $184M
2019 $312M
2020 $70M
Dec 20 1/2 yearly $191M
Total impairments of just under $758M
So only $109M of impairments to go before the entire Teva deal is written off and then it's bluesky for Mayne after that!!!
Chartsshout - just because I probably need to spell it out for you. The "blue sky for Mayne" statement is ironic.
General Discussion Topics, page-123
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.84 |
Change
-0.040(0.82%) |
Mkt cap ! $404.9M | |||
| Open | High | Low | Value | Volume |
| $5.01 | $5.02 | $4.75 | $488.3K | 101.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 818 | $4.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.85 | 165 | 4 |
View Market Depth
| Last trade - 14.17pm 15/11/2024 (20 minute delay) ? |
| MYX (ASX) Chart |